Transformation to diffuse large B-cell lymphoma (DLBCL) is a recognized, but unpredictable, clinical inflection point in the natural history of indolent lymphomas. Large retrospective studies highlight a wide variability in the incidence of transformation across the indolent lymphomas and the adverse outcomes associated with transformed lymphomas. Opportunities to dissect the biology of transformed indolent lymphomas have arisen with evolving technologies and unique tissue collections enabling a growing appreciation, particularly, of their genetic basis, how they relate to the preceding indolent lymphomas and the comparative biology with de novo DLBCL. This review summarizes our current understanding of both the clinical and biological aspects of transformed lymphomas and the outstanding questions that remain.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/j.seminhematol.2023.11.002 | DOI Listing |
Leuk Lymphoma
January 2025
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hum Pathol
January 2025
University Health Network and University of Toronto, Canada.
Indolent clonal lymphoid disorders are not recognized as lymphomas as they generally need no systemic treatment, and depending on the lesion, need only limited clinical follow-up. These lesions are usually incidentally diagnosed during the work up for other disease. The recognition of indolent clonal lymphoid disorders is important to avoid misdiagnosis as lymphoma and unnecessary treatment.
View Article and Find Full Text PDFBr J Haematol
January 2025
Department of Nursing, Tohoku Fukushi University, Sendai, Japan.
Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty-one patients received zandelisib orally at 60 mg daily continuously in the first two 28-day cycles, followed by intermittent dosing on Days 1-7 following each cycle until progressive disease or unacceptable toxicity.
View Article and Find Full Text PDFCureus
December 2024
Musculoskeletal Radiology, Fleury Group, São Paulo, BRA.
Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma subtype, posing challenges in prognostication. While interim PET/CT is a recognized response assessment tool in other lymphoma subtypes, its prognostic value for FL remains uncertain. This study aims to evaluate the significance of interim PET results, which were assessed using the Deauville Score.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!